Osaic Holdings’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-277
| Closed | -$5.08K | – | 7709 |
|
|
2024
Q2 | $5.08K | Sell |
277
-115
| -29% | -$2.1K | ﹤0.01% | 6162 |
|
|
2024
Q1 | $7.25K | Hold |
392
| – | – | ﹤0.01% | 5920 |
|
|
2023
Q4 | $7.69K | Sell |
392
-3,433
| -90% | -$59.9K | ﹤0.01% | 5969 |
|
|
2023
Q3 | $68.5K | Sell |
3,825
-213
| -5% | -$4.16K | ﹤0.01% | 4776 |
|
|
2023
Q2 | $83.3K | Sell |
4,038
-1,649
| -29% | -$34.5K | ﹤0.01% | 4572 |
|
|
2023
Q1 | $117K | Sell |
5,687
-2,026
| -26% | -$45.4K | ﹤0.01% | 4314 |
|
|
2022
Q4 | $172K | Buy |
7,713
+5,513
| +251% | +$124K | ﹤0.01% | 3988 |
|
|
2022
Q3 | $45K | Sell |
2,200
-772
| -26% | -$18.8K | ﹤0.01% | 5005 |
|
|
2022
Q2 | $70K | Sell |
2,972
-1,211
| -29% | -$28.8K | ﹤0.01% | 4698 |
|
|
2022
Q1 | $58K | Sell |
4,183
-17,271
| -81% | -$486K | ﹤0.01% | 4997 |
|
|
2021
Q4 | $764K | Sell |
21,454
-3,402
| -14% | -$128K | ﹤0.01% | 2650 |
|
|
2021
Q3 | $1.01M | Sell |
24,856
-437
| -2% | -$18.4K | ﹤0.01% | 2336 |
|
|
2021
Q2 | $1.01M | Sell |
25,293
-610
| -2% | -$22.8K | ﹤0.01% | 2344 |
|
|
2021
Q1 | $917K | Sell |
25,903
-6,535
| -20% | -$245K | ﹤0.01% | 2308 |
|
|
2020
Q4 | $1.01M | Sell |
32,438
-14,875
| -31% | -$453K | ﹤0.01% | 2026 |
|
|
2020
Q3 | $1.31M | Buy |
+47,313
| New | +$1.39M | ﹤0.01% | 1631 |
|
Other funds holding GERM
Osaic Holdings's GERM Position: Q3 2024 in Review
Osaic Holdings sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 277 shares — an estimated $5.08K sold.
Osaic Holdings first reported a position in GERM in Q3 2020 and held it in 16 quarters. The position peaked at $1.31M in Q3 2020. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.
- Osaic Holdings reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
- Osaic Holdings sold 277 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $5.08K.
- Osaic Holdings first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 16 quarters.
- Osaic Holdings's Amplify Treatments, Testing and Advancements ETF position peaked at $1.31M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.
Based on Osaic Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.